Improving Outcomes for Patients With CML: The Latest on TKIs and Combination Treatment Approaches

Join us to learn about the latest guidance and clinical data on the management of patients with CML using TKIs and combination treatment strategies, presented by expert faculty in an on-demand webcast archived from a live Webinar, plus downloadable slidesets from the Webinar, podcasts, and a ClinicalThought commentary.   
person default
Prof. Dr. med. Tim Henrik Brümmendorf
Jorge Cortes, MD
person default
Carlo Gambacorti-Passerini, MD

On-Demand Webcast

Gain expert insight on the latest evidence on TKI therapy and combination approaches for improving outcomes in chronic-phase CML by watching this on-demand Webcast.

person default Prof. Dr. med. Tim Henrik Brümmendorf Jorge Cortes, MD person default Carlo Gambacorti-Passerini, MD Physicians: maximum of 1.75 AMA PRA Category 1 Credits Released: September 11, 2020 Expired: September 10, 2021

Podcast

Listen to leukemia experts Prof. Dr. med Tim Henrik Brümmendorf; Jorge Cortes, MD; and Carlo Gambacorti-Passerini, MD, answer audience questions from live CCO Webinars on optimizing TKI treatments for patients with chronic-phase chronic myeloid leukemia (CML).

person default Prof. Dr. med. Tim Henrik Brümmendorf Jorge Cortes, MD person default Carlo Gambacorti-Passerini, MD Released: August 13, 2020

Downloadable Slideset

Downloadable ExpressPoints summary slides with key points related to the optimal treatment of chronic phase CML with TKIs.

person default Prof. Dr. med. Tim Henrik Brümmendorf Jorge Cortes, MD person default Carlo Gambacorti-Passerini, MD Released: July 14, 2020

Downloadable slides with expert analysis of first-line treatment of CP CML with TKIs.

person default Prof. Dr. med. Tim Henrik Brümmendorf Released: June 17, 2020

Downloadable slides with expert analysis of CML management after TKI inhibitor intolerance.

person default Carlo Gambacorti-Passerini, MD Released: June 17, 2020

Downloadable slides with expert analysis of second-line treatment of CP CML with TKIs after disease progression.

Jorge Cortes, MD Released: July 8, 2020

ClinicalThought

How are you managing your patients with CML after achieving a complete molecular remission on first-line TKI therapy? In this commentary, Prof. Brümmendorf shares his thoughts on treatment-free remission in patients with CML.

person default Prof. Dr. med. Tim Henrik Brümmendorf Released: September 21, 2020
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Pfizer Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue